ClinicalTrials.gg
RecruitingNCT07585968Updated Oct 26, 2026

Safety and Effectiveness of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere VT)

An interventional study of Sphere-9 Catheter with the Affera Mapping and Ablation System in Ventricular Tachycardia, sponsored by Medtronic Cardiac Ablation Solutions. Recruiting at 7 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Medtronic Cardiac Ablation Solutions (part of Medtronic) · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Oct 26, 20263 sites addedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
260
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Sphere VT is a prospective, multi-center, single-arm, unblinded pivotal clinical study. Adult subjects with recurrent, sustained, monomorphic ventricular tachycardia (MMVT) due to prior myocardial infarction (MI) will be enrolled and treated with the Sphere-9 Catheter and Affera Ablation System.

02

Conditions studied

  • Ventricular Tachycardia

Keywords

  • Recurrent sustained scar-related monomorphic ventricular tachycardia
  • Ventricular tachycardia
  • Arrhythmias, Cardiac
  • Heart Diseases
  • Cardiovascular Diseases
  • Pathologic Processes
  • Ischemic heart disease
  • Patient with Implantable Cardioverter Defibrillator (ICD)
  • Ischemic cardiomyopathy
03

In context

Tachycardia, Ventricular

451 studies on the registry are indexed under Tachycardia, Ventricular; 120 are open to participants now.

This study's planned enrollment of 260 is above the median of 71 across 280 interventional studies indexed under Tachycardia, Ventricular.

Browse Tachycardia, Ventricular studies →

Lead sponsor

Medtronic Cardiac Ablation Solutions is the lead sponsor of 37 studies on the registry; 9 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 8 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Prior myocardial infarction (MI).
  2. At least one episode of sustained (continuous for >30 seconds or requiring ICD intervention for termination) monomorphic ventricular tachycardia within the 6 months prior to enrollment.
  3. Recurrence of sustained ventricular tachycardia despite Class I or III antiarrhythmic drug therapy or ICD intervention.
  4. Implanted with an implantable cardiac defibrillator (ICD) or CRT-D for at least 2 months prior to the ablation procedure.
  5. Age 18 through 85 years old.
  6. Willing and able to provide .
  7. Willing and able to comply with all pre-, post-, and follow-up testing requirements.

Exclusion criteria

Exclusion Criteria:

  1. Incessant VT necessitating hemodynamic support prior to the ablation procedure.
  2. Unstable polymorphic VT or ventricular fibrillation (VF).
  3. Idiopathic VT or VT of non-ischemic cardiomyopathy.
  4. VT secondary to electrolyte imbalance, active thyroid disease, or any other reversible or non-cardiac cause (e.g., drug-induced arrhythmia).
  5. VT or VF thought to be from channelopathies.
  6. More than two prior VT ablations at any time, more than one prior VT ablation within 12 months prior to the ablation procedure, or any VT ablation within 4 weeks prior to the ablation procedure.
  7. Sarcoidosis.
  8. Hypertrophic cardiomyopathy, except when due to an apical aneurysm.
  9. Unstable angina.
  10. Active myocardial ischemia.
  11. Type 1 myocardial infarction within 2 months (60 days) prior to the ablation procedure.
  12. Any percutaneous coronary intervention performed in a setting of unstable angina or acute MI (STEMI or non-STEMI) within 2 months (60 days) prior to the ablation procedure. Note: elective PCI performed during elective angiogram would be excluded only if occurring within 30 days prior to the ablation procedure.
  13. Any cardiac surgery within 2 months (60 days) prior to the ablation procedure. Note: ICD lead implant/replacement falls under this exclusion, but ICD generator-only replacement does not.
  14. (LVEF) \<15%.
  15. Class IV heart failure.
  16. Decompensated heart failure.
  17. Extravascular ICD (EV-ICD) or subcutaneous ICD (S-ICD)
  18. Currently receiving support, or anticipated to receive support prior to the index ablation procedure, via extracorporeal membrane oxygenation (ECMO).
  19. Circulatory/ventricular assist device (VAD; surgical or percutaneous) implanted, planned or required for the procedure.
  20. Severe aortic or mitral stenosis, or severe aortic or mitral regurgitation.
  21. Presence of prosthetic valve in the aortic or mitral valve.
  22. Patients with advanced (on home oxygen).
  23. Presence of intracardiac tumor or other abnormality that precludes vascular access, catheter introduction, or manipulation.
  24. Thromboembolic event (stroke or ) within 6 months (180 days) prior to the index ablation procedure or with neurologic deficit.
  25. Left atrium (LA) or left ventricle (LV) intracardiac thrombus on imaging.
  26. Severe bleeding, clotting or thrombotic disorder, or thrombocytopenia (defined as count \<80,000).
  27. to anticoagulation.
  28. End-stage renal disease (requiring dialysis).
  29. Acute illness, active infection, or sepsis.
  30. less than 12 months.
  31. Any woman known to be pregnant or breastfeeding, or any woman of who is not on a reliable form of birth regulation method or abstinence.
  32. >45 kg/m2.
  33. Known ongoing drug or alcohol dependency.
  34. Current or anticipated participation in any other ongoing study of a drug, device, or biologic during the duration of the study not pre-approved by the Sponsor.
  35. Vulnerable subjects (such as a prisoner, handicapped or mentally disabled person, or person under tutelage or guardianship).
  36. Any other condition that, in the opinion of the investigator, would preclude enrollment in this study or compliance with follow-up requirements or would pose a significant hazard to the subject if an ablation procedure were performed.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    Ventricular tachycardia catheter ablation

    Ablation using the Sphere-9 Catheter with the Affera Mapping and Ablation System

    Device: Sphere-9 Catheter with the Affera Mapping and Ablation System

Interventions

  • DeviceSphere-9 Catheter with the Affera Mapping and Ablation System

    Adult subjects with ventricular tachycardia will be enrolled and undergo ablation with the Sphere-9 Catheter with the Affera Mapping and Ablation System.

06

What researchers measure

Primary outcomes

  1. Primary Safety

    A pre-defined list of device- or procedure-related SAEs, as adjudicated by the Clinical Events Committee (CEC), occurring within 7 days after the index ablation procedure (or within 3 months after the index ablation procedure for any esophago-pericardial fistula/esophageal perforation) will be considered a primary safety event.

    Time frame: As applicable, within 7 days or 3 months after the index ablation procedure

  2. Primary Effectiveness

    Freedom from recurrence of sustained monomorphic VT (MMVT) in the absence of new or increased dose of Class I or III antiarrhythmic drugs (AAD) through 6 months after the index ablation procedure.

    Time frame: Through 6 months after the index ablation procedure

07

Study locations

5 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Mar 2028, 19 months after the start.

Of 40 industry-sponsored interventional studies with no phase under Tachycardia, Ventricular, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 52. This study's planned 19 months is below that.

Counting every sponsor, half of 125 studies reached it within 36 months; a quarter within 20 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2026
First posted
May 14, 2026
StartActual
Aug 17, 2026
Primary completionEst.
Mar 2028
CompletionEst.
Sep 2028
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added
Show 3 added (3 United States)
  • Ascension Saint Vincent Hospital - Indianapolis · Indianapolis, United States
  • NYU Langone Medical Center · New York, United States
  • South Denver Cardiology Associates · Littleton, United States
across 3 updates, Sep 29, 2026 – Oct 26, 2026
Show all 3 updates
  1. Oct 26, 2026
    1 site added
    Show site
    • South Denver Cardiology Associates · Littleton, United States
  2. Oct 13, 2026
    1 site added
    Show site
    • NYU Langone Medical Center · New York, United States
  3. Sep 29, 2026
    1 site added
    Show site
    • Ascension Saint Vincent Hospital - Indianapolis · Indianapolis, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07585968
Responsible party
Sponsor
First posted
May 14, 2026
Start date
Aug 17, 2026
Primary completion
Mar 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Oct 26, 2026

Study contacts

Josh Treadway
Contact
josh.b.treadway@medtronic.com
817-412-0608
Mckenna Jones
Contact
mckenna.jones@medtronic.com
720-837-3089
Vivek Reddy, MD
principal investigator · Icahn School of Medicine at Mount Sinai
Pasquale Santangeli, MD
principal investigator · The Cleveland Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion